Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

NCT00895895 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00895895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00895895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2009
Completion date
May 31, 2011
Enrollment
526 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease